Rare de novo acute leukemias of mature B cells may exhibit the chromosomal translocation t(l4;18)(q32.3; q21.3). We report the preliminary characterization of t w o cases that exhibited not only t(l4;18)(q32.3;q21.3) but also the novel translocation t(8;9)(q24.1; pl3.3), involving the C-MYC locus with unknown sequences at 9~1 3 . 3 . From these cases, two Epstein-Barr virus negative cell lines (Karpas 231 and 353) with features identical to those seen in fresh cells from the patient have been derived. Both cell lines have complex karyotypes: in addition to both t(14;18)(q32.3;q21.3) and t(8;9)(q24.l;p13.3), cell line Karpas 231 exhibited three-way translocation t(l;3;11) (q42.3;q27.1 ;q23.1), whereas Karpas 353 exhibited t(1;3;7)(~32.1;q21.1;q22.1). Both cases retained immunophenotypes characteristic of mature B cells with no evidence for commitment to other hematopoietic lineages. Both cases expressed abundant, normal-sized C-MYC transcript, but no rearrangement of C-MYC DNA sequences could be detected using probes that span 80 kb HE CHROMOSOMAL translocation t( 14; 18)(q32.3; T q2 1.3) is the most common cytogenetic abnormality in B-cell malignancies being detected in some 80% of follicular and 30% of diffuse B cell non-Hodgkin lymphoma (B-NHL).' The molecular consequences of this translocation are marked overexpression of the BCL-2 gene that is normally downregulated in mature B cell^.^,^ However, overexpression of BCL-2 per se appears insufficient to produce the malignant phenotype; rather, BCL-2 expression appears to prevent programmed cell death or apopt~sis.~ For example, BCL-2 transgenic mice do not have a greatly increased incidence of B-cell malignancies but massive polyclonal B-cell expansion? acquisition of further abnormalities results in the development of monoclonal Similarly, using polymerase chain reaction (PCR) strategies it has been possible to obtain molecular evidence for the t( 14;18)(q32.3;q21.3) in reactive lymph nodes and peripheral blood (PB) of normal, healthy individuals.' These data indicate the necessity for several events over and above BCL-2 deregulation for the development of B-cell malignancy.'aLO These events may include concurrent activation of synergistic oncogenes" and inactivation of tumor-suppressor genes.'* The t( 14;18)(q32.3;q21.3) may also be observed in rare cases of de novo acute leukemia, with no documented antecedent B-NHL. These leukemias are extremely aggressive and respond poorly, if at all, to present chemotherapy prot o c o l~. '~-'~ Most, but not all, have in addition to the t( 14; 18)(q32.3;q21.3), translocations involving the C-MYC locus with the Ig heavy-chain or light-chain loci, data that confirm the synergistic actions of concurrent deregulation of C-MYC and BCL-2 genes observed both in vitro and in transgenic mouse experiment^.^,^^'^,'^ We report here the preliminary characterization of two new cell lines derived from patients with de novo acute leukemia of mature B cells that exhibited translocation t( 14;18)(q32.3;q21.3) and additionally a novel rearrange- ment involving the C-MYC locus with a region on the short arm of chromosome 9, namely t(8;9)(q24.l;pl3.3). This combination of cytogenetic abnormalities has been previously described in diffuse B-NHL and associated with a poor response to therapy" but has not been associated with acute transformation. These cell lines will be useful in determining the nature of sequences at chromosome 9pl3.3 and other events that contribute to the acquisition ofthe biologically aggressive leukemic phenotype.
T q2 1.3) is the most common cytogenetic abnormality in B-cell malignancies being detected in some 80% of follicular and 30% of diffuse B cell non-Hodgkin lymphoma (B-NHL).' The molecular consequences of this translocation are marked overexpression of the BCL-2 gene that is normally downregulated in mature B cell^.^,^ However, overexpression of BCL-2 per se appears insufficient to produce the malignant phenotype; rather, BCL-2 expression appears to prevent programmed cell death or apopt~sis.~ For example, BCL-2 transgenic mice do not have a greatly increased incidence of B-cell malignancies but massive polyclonal B-cell expansion? acquisition of further abnormalities results in the development of monoclonal Similarly, using polymerase chain reaction (PCR) strategies it has been possible to obtain molecular evidence for the t( 14;18)(q32.3;q21.3) in reactive lymph nodes and peripheral blood (PB) of normal, healthy individuals.' These data indicate the necessity for several events over and above BCL-2 deregulation for the development of B-cell malignancy.'aLO These events may include concurrent activation of synergistic oncogenes" and inactivation of tumor-suppressor genes.'* The t( 14;18)(q32.3;q21.3) may also be observed in rare cases of de novo acute leukemia, with no documented antecedent B-NHL. These leukemias are extremely aggressive and respond poorly, if at all, to present chemotherapy prot o c o l~. '~-'~ Most, but not all, have in addition to the t( 14; 18)(q32.3;q21.3), translocations involving the C-MYC locus with the Ig heavy-chain or light-chain loci, data that confirm the synergistic actions of concurrent deregulation of C-MYC and BCL-2 genes observed both in vitro and in transgenic mouse experiment^.^,^^'^,'^ We report here the preliminary characterization of two new cell lines derived from patients with de novo acute leukemia of mature B cells that exhibited translocation t( 14;18)(q32.3;q21.3) and additionally a novel rearrangearound the C-MYC coding sequences. Breakpoints within the BCL-2 gene were divergent. In Karpas 353 the BCL-2 breakpoint occurred within the 3 untranslated major breakpoint region (mbr) of the gene, whereas, in Karpas 231, breaks in both the 3 mbr and in the region 5' of the gene were detected. The cytogenetic combination of t(14;18)(q32.3;q21.3) and t(8;9)(q24.1; pl3.3) has been previously reported in diffuse B cell lymphomas. This combination may be a new recurrent abnormality, of central pathogenic importance in the transformation of B cells to high grade malignancies through simultaneous deregulation of BCL-2 and C-MYC genes, constitutive expression of C-MYC being driven by currently unknown DNA sequences on chromosome 9~1 3 . 3 .
The presence of other complex translocations including those affecting 1 1 q23.1 may further accelerate the process of acute transformation.
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ment involving the C-MYC locus with a region on the short arm of chromosome 9, namely t(8;9)(q24.l;pl3.3). This combination of cytogenetic abnormalities has been previously described in diffuse B-NHL and associated with a poor response to therapy" but has not been associated with acute transformation. These cell lines will be useful in determining the nature of sequences at chromosome 9pl3.3 and other events that contribute to the acquisition ofthe biologically aggressive leukemic phenotype.
CASE REPORTS

Case One
A 7 I-year-old woman who had been previously well was admitted in September I988 with septicemia. Physical examination showed no lymphadenopathy and no hepatosplenomegaly. 
Case Two
A 60-year-old woman was admitted in November 1988 with hematemesis and melaena. She was on no medication and had been otherwise well. Physical examination showed moderate splenomegaly (6 cm below the costal margin), but there was no lymphadenopathy. Chest X ray (CXR) was normal. FBC showed hemoglobin 1 1 1 g/L; WBC count 22.5 X 109/L and platelets 56 X 109/L. The cell line Karpas 353 was derived from this blood sample. The blasts had cytologic appearances consistent with FAB type L2. Limited immunophenotyping at diagnosis showed expression of CD19, CD 10, and TdT, but no expression of CDI 3 and CD33; studies of expression of surface and cytoplasmic Ig were not performed. A BM aspirate showed complete replacement by blasts, and therapy was begun with intravenous (IV) daunorubicin, vincristine, and L-asparaginase along with oral prednisolone. She attained complete remission six weeks later and was given further IV combination chemotherapy. She became profoundly pancytopenic, developed renal failure, and died shortly afterwards from septicemia.
MATERIALS AND METHODS
Cell Culture and Chromosome Studies
PB cells were cultured in RPMI medium using culture conditions similar to those described previously.21 The cell lines (Karpas 23 I and 353) have been maintained in continuous culture since Autumn 1988. Cells were harvested by conventional methods 24 hours after the initiation ofculture and at intervals thereafter. Slides were G-banded with Wright's stain. High resolution (HR) chromosome banding analysis was performed with the aid of a computerbased image analysis system (BIOS; Digital Scientific, Cambridge, UK). The ISCN 85 nomenclature has been used to describe the abnormal chromosome markers.22
Immunophenotyping
Cell-surface antigen expression was studied by flow cytometry on a FACS I1 flow cytometer (Becton Dickinson, Sunnyvale, CA) as described previou~ly.~~ Cytoplasmic antigen expression was assessed by means of a modified alkaline phosphatase antialkaline phosphatase te~hnique.'~ Monoclonal antibodies (MoAbs) of the CAMPATH and YTH seriesz5 were kindly provided by Dr Geoff Hale and Professor Herman Waldmann, Department of Therapeutic Immunology, University of Cambridge, UK. Other MoAbs and polyclonal antibodies were attained commercially.
Genotypic Analysis
DNA blot analysis was performed as previously described.26 Briefly, IO pg of high molecular weight DNA was digested with restriction endonucleases, electrophoresed in 0.6% to 0.8% agarose and transferred to positively-charged nylon membranes (Hybond N+; Amersham, UK) by overnight capillary transfer in 1.5 mol/L NaCI, 0.25 mol/L NaoH. Filters were hybridized with radioactively labeled probes in a Techne HB-1 hybridization chamber (Cambridge, UK)'? washed to a final stringency of 0.1 X SSC (SSC is 0.15 mol/L NaCI, 0.0 I5 mol/L trisodium citrate), and then autoradiographed for between 5 and 48 hours with intensifying screens at -80°C.
The derivation and properties of most DNA probes used in this study have been described
The location of the C-MYC probes with respect to the C-MYC gene are shown in Fig 1: the full-length C-MYC cDNA clone CD1AZ9 was obtained from Dr T. Rabbitts (Laboratory of Molecular Biology, Cambridge UK) while the three 3' genomic clones pCAl.7.5, pPA I .3SB, and ~P A 0 . 2 5~' were obtained from Dr Louis Showe (Wistar Institute, Philadelphia, PA). The BCL-2 probes used were: (1) for the major breakpoint region (mbr) pFL-1 ,3' (2) for the minor cluster region (mcr) pFL-2;' and (3) for the 5' first and second exons of BCL-2 a 1.6 kb EcoRI cDNA clone, pB16." PCR amplification of the t( 14; 18) translocation breakpoints was attempted using primers and methods described by Cotter et al. 34 Probe pKIS, derived from the molecular cloning of t(9;14)(pl3;q32) in a case of CD30+ B-NHL was obtained from T Honjo (Kyoto, Japan)."
All probes were used as gel-purified inserts and labeled to a specific activity of approximately 2 X lo9 disintegrations per minute per pg DNA by the method of ~ligo-priming.~~
RNA Analysis
Total RNA was extracted from cultured cells by lysis in guanidium isothiocyanate and phenol e~traction.'~ mRNA was subsequently isolated using biotin-labeled oligo (dT) and streptavidincoated paramagnetic beads (Promega, UK). RNA samples were electrophoresed in agarose containing formaldehyde and blotted in 20 X SSC to neutral nylon membranes (Hybond-N; Amersham, UK). Quantitation of the amount of mRNA applied and assessment of mRNA integrity were assessed by probing with a glyceraldehyde 3 phosphate dehydrogenase full-length cDNA probe.
Virological Studies
To determine whether the cell lines Karpas 231 and 353 were infected with Epstein-Barr Virus (EBV), cells were dried on multiwell glass slides and fixed by acetone. Thereafter, the 231 and 353 cells, as well as control EBV-positive (Karpas 160) and negative cells (Karpas 422), were incubated with human serum containing a high titer of antibodies to EBV (at a dilution of 1: 10). This cell test was developed in the same way as described for human immunodeficiency virus' (HIV)+ serum.38
In an attempt to induce potentially latent virus-like particles (VLP) cell lines Karpas 23 I and 353 were cultured for 24 hours in medium containing 30 pg/mL 5-bromo-2-deoxyuridine (BUDR). After the incubation with BUDR the cells were cultured for a further 48 hours in normal growth medium before they were fixed in glutaraldehyde and stained in uranyl acetate and lead citrate. Ultrathin sections were examined by transmission electron microscopy.39
RESULTS
Chromosome Studies
Initial chromosome analysis was performed after 24 hours culture. Thereafter, cells were monitored cytogenetically during long-term cultivation at intervals of about 3 weeks.
For personal use only. on October 25, 2017. by guest www.bloodjournal.org From Fig 2. The minor clone has two structural rearrangements, the reciprocal translocations t( 14;18)(q32.3;q21.3) and t(8;9)(q24.1;p13.3). The major clone has additional structural rearrangements shown in the partial karyotypes (Fig 3) . These include: ( I ) a further threeway rearrangement interpreted as t( 1;3; I l)(q42.3;q27.1; q23.1), (2) an abnormal chromosome 17 with a strong Giemsa positive band inserted at 1 7~1 3 , (3) an extra chromosome 13 with an interstitial deletion 13q 12.3 q2 1.2, (4) an extra copy of the 18q(-) marker; and (5) two copies of both partners ofthe t(8;9)(q24.2;p 13.3). The last two abnormalities were found only in some cells of the major clone.
Cell line Karpas 353. All eloid differentiation antigens. In contrast. mice expressing both BCL-2 and C-MYC transgenes develop tumors of an apparently primitive progenitor cell population. ' Immunocytochemistry with anti-BCL-2 antibodies showed strong expression of BCL-2 in both cell lines; immuno-electron-microscopy localized this expression to predominantly the outer mitochondrial membrane in both these and other B-cell lines with t( 14;18).42 DNA and RNA Smdics High molecular weight DNA extracted from fresh leukemic blasts and cell lines Karpas 23 I and 353 was digested with restriction endonucleases including EcoRI, HindlII, BamHI, BgIII, Pstl, Kpnl, and EcoRV; and probed with a variety of oncogene and Ig and T-cell receptor (TCR) DNA probes. Identical results were obtained with fresh and cultured cells and are summarized in Table 2 . In view of the observed cytogenetic abnormalities, particular emphasis was placed on analysis of C-MYC and BCL-2 genes.
C-MYC. No rearrangements of either C-MYC coding sequences or its immediate 5' or 3' flanking sequences were detected in Karpas 23 I or 353 cell lines. Threefold to fourfold amplification of the C-MYC sequences consistent with the observed cytogenetic abnormalities was observed in K23 1 cell line. Using the four probes illustrated. the area analyzed spans about 80 kb around C-MYC in BamHI, Kpnl and EcoRV digests. However, both cell lines showed abundant C-MYC expression by Northern blot analysis (Fig I) .
BCL-2. Cell line Karpas 353 exhibited rearrangement of the mbr of BCL-2 as detected by probe pFL-I. the rearranged pFL-1 fragment comigrating with a rearranged IgJH allele (Fig 5) . PCR amplification using mbr and con- 
L 'irological Siiidim
No staining with anti-ERV antisera was observed in either Karpas23 1 or 353 cell lines. Similarly. ultrastructural examination of bromodeoxyuridine (RUDR)-treated cells did not show monophologically distinct viral particles nor cytoplasmic inclusions with virus-like particles.
DISCUSSION
B-cell malignancies with t( 14:18)(q32.3:q2 1.3) comprise a spectrum of disease ranging from slow-growing follicular R-NHL that may require little or no therapy for many years, to highly aggressive acute leukemiasofmature Rcells, refractory to intensive combination chemotherapy. Such leukemias may arise with or without an antecedent lymphomatous phase.
For .2; pl3.3),t(l4;18)(q32.3;q21.3) .
The molecular dissection of the events underlying leukemic transformation may have clinical importance not only in the design of specific, targeted therapies, but also in the formulation of prognostic subgroups of B-NHL. comparable with those used in B cell prccursor ALL.45 It isclear from both clinicalw8 and experimental studies6 that deregulation of C-MYC expression in B cells with deregulated BCL-2 can play a major role in this transformation. However. not all acute leukemias with t( 14:18)(q32.3;q2 I .3) and similarly only about 50% of tumors in RCL-2 transgenic mice have exhibited cytogenetically detectable C-MYC translocations indicating that other mechanisms may operate.6." Retroviral "tagging" experiments in mice have indicated a possible role for the PIM oncogene,'' although cytogenetic or molecular evidence for comparable activation in human tumors is currently lacking. Another possible mechanism is the loss of tumor-suppressor gene functions. A high incidence of p53 mutations has been shown in Burkitt's lymphoma,'* but no data have yet been reponed in acute leukemias with t( 14; I8)(q32.3;q2 I .3). In passing, it should be noted that both cell line Karpas 23 I and the first case described by Mufti et all3 in 1983 exhibited structural chromo- 
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References for the derivation of both lg and TCR probes used in this study are presented in references 26 and 28. "G" denotes germline configuration and "R" denotes rearranged. All 4 C-MYC probes used in this study retained germline configuration on conventional DNA blot analysis. Apparently rearranged fragments were observed in K23 1 DNA using both 5 and 3 BCL-2 DNA probes (Fig 5) : the significance of this observation is presently not clear. Otherwise both K231 and K353 have maintained the same biallelic rearranged lgJH fragments as seen in fresh leukemic cells (data not shown). K231 also has multiple rearranged lgCX fragments. Additionally, K231 also exhibited biallelic deletion of all TCR J6 and C6 segments suggestive of TCR Vn-Jn rearrangement: however, neither TCRy nor TCRB rearrangements could be detected.
soma1 abnormalitiesofboth 13q14, thesiteoftheretinoblastoma (Rb-I) gene, and 17~13, the site ofthe p53 gene. The significance of these observations is not yet clear.
We have derived cell lines from two patients with de novo acute leukemias of mature B cells that exhibit not only the t( 14: I8)(q32.3:q2 1.3) but also the novel C-MYC translocation t(8:9)(q24. I:pl3.3) in which the C-MYC locus at 8q24.1 becomes juxtaposed to unknown sequences on chromosome 9pl3.3. Despite the lack ofC-MYC rearrangement on conventional DNA blot. RNA analysis showed constitutive C-MYC expression in both cases, presumably The rearranged fragment seen in K231 DNA comigrated exactly with one of the t w o rearranged IgJH fragments.
2 3 4
A caused by the abnormal presence of DNA sequences at 9~13.3. Therefore, these cases appear to be analogous to variant C-MYC translocations in Burkitt's lymphoma where the breakpoints, although occurring several hundred kilobases from the C-MYC coding sequences, nevertheless result in deregulated C-MYC e x p r e s s i~n .~~.~~ We are presently attempting to map the breakpoints in the C-MYC locus by using fluorescent in situ-hybridization techn i q u e~.~~ The presence of the t(8;9)(q24.l;p13.3) in both cell lines suggests that this translocation may be of central pathogenic 
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For personal use only. on October 25, 2017 . by guest www.bloodjournal.org From importance in the transformation process. Evidence in support of this contention may be adduced from various sources. Firstly, the cytogenetically identical combination of t( 14;18)(q32.3;q21.3) and t(8;9)(q24.l;pl3.3) has been previously reported in two cases of diffuse B-NHL with poor response to therapy but without leukemic transformation2": no molecular data were reported. Secondly, in a report on three cases of de novo leukemia of mature B cells with t( 14; 18)(q32.3;q2 1.3) two patients had involvement of chromosome 9: in one case, deletion of the short arm was accompanied by an abnormal chromosome 8, defined at 8q+ that from the illustration could have been interpreted as the result of a t(8;9) similar to those present in the Karpas 231 and 353 cell lines.'' Thirdly, an apparently related translocation t(9;14)(pI 3;q32) has been reported in lymphoplasmacytic B-NHL.44 Molecular cloning experiments have been performed in a case of CD30' anaplastic B-NHL using Ig probes to isolate DNA sequences from chromosome 9pl 3.35 These sequences apparently encoded an 1 1-kb mRNA. This locus does not appear to be involved in either Karpas 231 or 353. Finally, a new recurrent translocation t(9;20)(p13;qlI) has been recently identified in cases of Bcell precursor (BCP) ALL." The relationship ofthese abnormalities and the deletions of short arm of chromosome 9 commonly seen in BCP-ALL" to the t(8;9)(q24.l;p13.3) seen in B-NHL and leukemias with the t(14;18)(q32.3; q2 1.3) remains to be determined.
The translocation of C-MYC to loci outside the Ig loci in B-cell malignancies is becoming increasingly recognized. C-MYC has been identified as being translocated to a t( 14;18)(q32.3;q2 1.3) in the B-NHL cell line SU-DL-6,53 to chromosome 17q22 in a case of aggressive prolymphocytic leukemia,54 and to chromosome 12q22 in a case of transformed B-cell chronic lymphocytic leukemia.s5 We have observed C-MYC being translocated to chromosome 2p14 telomeric to the Ig K locus in B-ALL supravening follicular B-NHL. (M.J.S.D., E.N., manuscript in preparation). Also in the B-ALL cell line Wien I 33,s6 C-MYC has been found to be translocated to unidentified sequences on chromosome 12q24.1. (N. Asou, M.J.S.D., E.N., V. J. Zani; manuscript in preparation). Despite the cytologic diversity of these cases and the variety of partner chromosomes involved, it is of interest that most of these cases represent disease in transformation.
Therefore, the question arises as to whether the combination of BCL-2 and C-MYC deregulation alone is sufficient to generate the full leukemic phenotype or whether additional events are necessary. Analysis is complicated by the fact that many leukemias with t( 14;18)(q32.3;q21.3) and 8q24.1 rearrangements have complex karyotypes with multiple abnormalities. There are as yet no reports of additional common chromosome abnormalities, but in many cases precise definition of the chromosomes has not been possible. In the cell lines Karpas 231 and 353, high resolution banding studies have defined two three-way translocation t(1;3;1 l)(q42.3;q27.1;q23.1) and t(1;3;7)(~32.1;q21.1; q22. I), respectively. The significance of such rearrangements is not yet known but the involvement of breakpoints described in other B-NHL such as 3q2757 and 1 lq23.I2' should be noted. It seems likely that these translocations may also result in deregulated expression of presently unrecognized oncogenes. The availability and the further characterization of the cell lines Karpas 23 1 and 353 facilitate the study of the events that lead to the leukemic transformation of B cells.
